Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial
Crossref DOI link: https://doi.org/10.1186/s40425-016-0137-x
Published Online: 2016-06-21
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gray, H. J.
Benigno, B.
Berek, J.
Chang, J.
Mason, J.
Mileshkin, L.
Mitchell, P.
Moradi, M.
Recio, F. O.
Michener, C. M.
Secord, A. Alvarez
Tchabo, N E.
Chan, J. K.
Young, J.
Kohrt, H.
Gargosky, S. E.
Goh, J. C.
Funding for this research was provided by:
Prima BioMed